world-cancer-2017-scientifictracks-abstracts

21 / 28

Page 46
Notes:
conferenceseries.com
Volume 9, Issue 9 (Suppl) J Cancer Sci Ther, an open access journal
ISSN: 1948-5956 World Cancer 2017
October 19-21, 2017
25th WORLD CANCER CONFERENCE
October 19-21, 2017 | Rome, Italy
An overview of the use of natural compounds to reduce drug resistance in cancer therapy: The role
of polysaccharide krestin
Manuela Boyle
University of New England, Australia
Introduction & Aim: Cancer cells are better able to adapt to stress than normal cells. In cancer treatment, this adaptation
results in tumor cells that develop cancer resistance to chemotherapy drugs. This event is usually the primary obstacle to
successful treatment. Finding themselves in a state of high alert, cancer cells have the ability to express resistance not only to
drugs they have been exposed to, but to any other noxious agent. Multi-drug resistance is a protection mechanism that can
lead to failure of the conventional cancer treatment. Research shows that natural compounds can reverse drug resistance by
inhibition of P-glycoprotein, inhibition of glutathione S-transferase drug detoxification system and inhibition of heat-shock
proteins. There is ample evidence suggesting that selected natural compounds can produce cytotoxic effects in cancer cell
through several mechanisms and that, when they are combined with chemotherapy drugs, these effects are often additive or
synergistic.
Method: A review of randomized controlled trails of the mechanisms by which cancer cells, exposed to chemotherapy, have
the ability to devise strategies for resistance and survival. This study involves the research of EBSCO, MEDLINE, and PubMed
from 1992 to 2012 to retrieve suitable articles. Five double blind placebo controlled clinical human and animal studies were
reviewed.
Results: All the control studies conducted in large multi-centre trials, confirmed improvement in patient survival on a
dose of 3 grams of PSK per day orally unless noted. 262 postoperative stomach cancer patients were randomized to receive
chemotherapy or chemotherapy and PSK. The addition of PSK increased the five-year disease-free rate (from 59% to 71%) and
the five year survival rate (from 60% to 73%). 462 patients with curatively resected colon cancer were randomized to receive
chemotherapy or chemotherapy plus PSK. The latter combination increased the eight-year disease free rate (from about 7.8%
to 28 %) and ten year survival rate (from 19% to 36%). 278 patients with stage II aT2N1 estrogen-dependent breast cancer were
randomized to receive chemotherapy or chemotherapy. The administration of PSK increased the five year survival rate (from
81% to 96%). Disease-free survival also increased. 38 patients with nasopharyngeal cancer who were treated with radiotherapy,
with or without chemotherapy, were randomized to receive PSK or no PSK. The addition of PSK increased survival rate (from
15 to 35 months). The PSK dose was 1 gram per day orally.
Conclusions: Dose-dependent of Polysaccharide-K (PSK) has shown anti-cancer potential in combination with conventional
therapies due to a combination of immune stimulation and inhibition of immuno suppressive cytokines.
Biography
Manuela Boyle is an Australian Integrative Oncologist with board certification by the Institute of Integrative Medicine (USA). With over 20 years of clinical experience
in Integrative Medical centres in Australia, Italy, United Kingdom and Singapore, she is a leading integrative oncology educator delivering training and mentoring to
medical doctors and allied health practitioners. She is a regularly invited guest speaker at key conferences around the globe and is the published author of several
peer-reviewed papers. In 2015, she was accepted as an external expert by the European Centre for Disease Prevention and Control in Stockholm, Sweden, an
honorary position aimed to provide independent scientific opinions, expert advice, data and information and to maintain scientific excellence at all times through the
best expertise available. She is the Director of Vingyana Integrative Oncology Clinic in Sri Lanka, a state of the art technology and residential medical centre, while
maintaining her presence at her clinics in Milano, London and the Gold Coast (Australia).
Manuela Boyle, J Cancer Sci Ther 2017, 9:9(Suppl)
DOI: 10.4172/1948-5956-C1-111